LYRA vs. FEMY, ALUR, NEPH, RVP, OSRH, QTI, CLGN, NXGL, IRIX, and PETV
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Femasys (FEMY), Allurion Technologies (ALUR), Nephros (NEPH), Retractable Technologies (RVP), OSR (OSRH), QT Imaging (QTI), CollPlant Biotechnologies (CLGN), NEXGEL (NXGL), IRIDEX (IRIX), and PetVivo (PETV). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs.
Lyra Therapeutics (NASDAQ:LYRA) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation, analyst recommendations and community ranking.
95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Femasys shares are held by institutional investors. 3.3% of Lyra Therapeutics shares are held by insiders. Comparatively, 12.3% of Femasys shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Lyra Therapeutics' average media sentiment score of 0.00 beat Femasys' score of -0.35 indicating that Lyra Therapeutics is being referred to more favorably in the media.
Lyra Therapeutics has a beta of 0.04, indicating that its stock price is 96% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.52, indicating that its stock price is 352% less volatile than the S&P 500.
Femasys has a net margin of -1,435.77% compared to Lyra Therapeutics' net margin of -6,635.76%. Lyra Therapeutics' return on equity of -125.07% beat Femasys' return on equity.
Femasys received 14 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 74.51% of users gave Femasys an outperform vote while only 58.54% of users gave Lyra Therapeutics an outperform vote.
Lyra Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 2,064.50%. Femasys has a consensus price target of $8.67, suggesting a potential upside of 717.61%. Given Lyra Therapeutics' higher possible upside, analysts clearly believe Lyra Therapeutics is more favorable than Femasys.
Femasys has higher revenue and earnings than Lyra Therapeutics. Femasys is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Femasys beats Lyra Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy LYRA Stock Free LYRA Stock Alerts